JP2007502283A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502283A5
JP2007502283A5 JP2006523322A JP2006523322A JP2007502283A5 JP 2007502283 A5 JP2007502283 A5 JP 2007502283A5 JP 2006523322 A JP2006523322 A JP 2006523322A JP 2006523322 A JP2006523322 A JP 2006523322A JP 2007502283 A5 JP2007502283 A5 JP 2007502283A5
Authority
JP
Japan
Prior art keywords
group
alkyl
cycloalkyl
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006523322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502283A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/025970 external-priority patent/WO2005019240A2/en
Publication of JP2007502283A publication Critical patent/JP2007502283A/ja
Publication of JP2007502283A5 publication Critical patent/JP2007502283A5/ja
Withdrawn legal-status Critical Current

Links

JP2006523322A 2003-08-13 2004-08-11 メラニン凝集ホルモン受容体アンタゴニスト Withdrawn JP2007502283A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49485503P 2003-08-13 2003-08-13
PCT/US2004/025970 WO2005019240A2 (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonists

Publications (2)

Publication Number Publication Date
JP2007502283A JP2007502283A (ja) 2007-02-08
JP2007502283A5 true JP2007502283A5 (enExample) 2007-06-28

Family

ID=34215905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523322A Withdrawn JP2007502283A (ja) 2003-08-13 2004-08-11 メラニン凝集ホルモン受容体アンタゴニスト

Country Status (7)

Country Link
US (1) US20050256161A1 (enExample)
EP (1) EP1654225A4 (enExample)
JP (1) JP2007502283A (enExample)
AU (1) AU2004266228A1 (enExample)
CA (1) CA2534428A1 (enExample)
MX (1) MXPA06001638A (enExample)
WO (1) WO2005019240A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418965C (zh) 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7645778B2 (en) * 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
BRPI0608653A2 (pt) * 2005-04-01 2010-11-30 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou um sal do mesmo
WO2007002634A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE485269T1 (de) * 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
AR056867A1 (es) * 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
US7816382B2 (en) * 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
AU2006298852A1 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as MCH receptor antagonists
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
PE20140913A1 (es) 2010-11-15 2014-08-22 Abbvie Inc Inhibidores de nampt y rock
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
MX2017012646A (es) * 2015-04-17 2018-01-24 Dow Agrosciences Llc Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
CN107949279A (zh) * 2015-07-06 2018-04-20 得克萨斯系统大学评议会 可用作用于治疗人类癌症的抗癌剂的苯甲酰胺或苯扎明化合物
KR102490246B1 (ko) * 2016-10-12 2023-01-20 코르테바 애그리사이언스 엘엘씨 살충 유용성을 갖는 분자, 및 그와 관련된 중간체, 조성물, 및 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2730174C2 (de) * 1977-07-04 1981-12-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Aminobenzoesäurederivate und Arzneimittel enthaltend solche Aminobenzoesäurederivate
ZA843899B (en) * 1983-05-23 1984-12-24 Usv Pharma Corp Compounds for treating hypertension
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6472394B1 (en) * 2000-12-22 2002-10-29 Schering Corporation MCH antagonists and their use in the treatment of obesity
DE10123958A1 (de) * 2001-05-17 2002-11-28 Aventis Pharma Gmbh Verfahren zur Identifizierung von Liganden für G protein coupled receptors
PE20021091A1 (es) * 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7084156B2 (en) * 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003087044A2 (en) * 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
WO2003087046A1 (en) * 2002-04-09 2003-10-23 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
US7078430B2 (en) * 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Similar Documents

Publication Publication Date Title
JP2007502283A5 (enExample)
JP6193922B2 (ja) ハロアルキルヘテロアリールベンズアミド化合物
ES2873949T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
TW444013B (en) Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia
RU2010129724A (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
JP4294960B2 (ja) 抗癌剤としてのサイクリン依存性キナーゼ阻害剤
RU2007111711A (ru) Производные трициклического лактама в качестве ингибиторов 11-бэта-гидроксистероидной дегидрогеназы
DE69208263T2 (de) Substituierte aminopyrimidine als angiotensin ii antagonisten
RU2009113585A (ru) Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
JP2010513322A5 (enExample)
JP2016053078A (ja) がん及び非新生物性状態の治療方法
JP2017533968A5 (enExample)
JP2013542996A5 (enExample)
ZA200603474B (en) Alkoxy substituted imidazoquinolines
JP2010502689A5 (enExample)
JO3429B1 (ar) مشتقات برميدينات مثبطة فيروس الايدز
JP2011507878A5 (enExample)
RU2010147404A (ru) Замещенные дигидропиразолоны в качестве ингибиторов hif-пролил-4-гидроксилазы
JP2007530601A5 (enExample)
JP2972377B2 (ja) カテコール誘導体、その薬学的に許容しうる塩およびエステルならびにそれらを含有する医薬組成物
CN1997366A (zh) 作为抗病毒剂的咪唑和噻唑衍生物
JP2011507879A5 (enExample)
AU2015346413A1 (en) Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
JP2020500866A5 (enExample)